Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04334759 · ClinicalTrials.gov registry record · Phase 3
DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma
A Phase 3 study, sponsored by PrECOG.
- Completed
- Registry status
- Phase 3
- Development phase
- 214
- Enrollment target
NCT04334759: Completed Phase 3 study, sponsored by PrECOG.
NCT04334759 is a Phase 3 study that has completed, run by PrECOG. The registered enrollment target is 214 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (72% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04334759, a Phase 3 study, has completed, sponsored by PrECOG.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 214 participants
- Enrollment target
Study Summary
Patients with pleural mesothelioma (PM) that cannot be surgically removed will receive standard chemotherapy (cisplatin or carboplatin and pemetrexed) given with durvalumab, a type of immunotherapy, or a treatment chosen by the study doctor, which is either standard chemotherapy or immunotherapy combination (ipilimumab and nivolumab). Durvalumab is an antibody (a type of human protein) that works by blocking a body substance called Programmed Death-Ligand 1 (PD-L1). Blocking PD-L1 helps the body's immune system attack cancer cells. Research has shown that durvalumab can slow tumor growth and shrink tumors in some people with cancer. Previous studies of combining durvalumab and chemotherapy showed that this combination is active in advanced mesothelioma. The purpose of this study is to see whether adding durvalumab to standard chemotherapy will improve overall survival (OS) in patients with PM.
Primary Outcome
Defined as the time from randomisation to the date of death due to any cause.
Interventions
- DRUG Durvalumab
- DRUG Standard Chemotherapy
- DRUG Ipilimumab and Nivolumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 214 participants |
| Start Date | 2021-02-18 |
| Est. Completion | 2025-06-30 |
| Phase | Phase 3 |
What the finished NCT04334759 record still lists
NCT04334759 is an interventional study that assigns participants to a tested intervention. The registered 214 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (72% lower).
The record links to 0 conditions, and to 3 interventions - of which Durvalumab is the first listed.
NCT04334759 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04334759 about?
NCT04334759 is a clinical study titled "DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma". Patients with pleural mesothelioma (PM) that cannot be surgically removed will receive standard chemotherapy (cisplatin or carboplatin and pemetrexed) given with durvalumab, a type of immunotherapy, or a treatment chosen by the study doctor, which is either standard chemotherapy or immunotherapy com...
What is the current status of trial NCT04334759?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 214 participants. The study started on 2021-02-18. Estimated completion is 2025-06-30.
What interventions are being tested in trial NCT04334759?
The interventions under investigation include: Durvalumab (DRUG), Standard Chemotherapy (DRUG), Ipilimumab and Nivolumab (DRUG).
Who is sponsoring clinical trial NCT04334759?
This trial is sponsored by PrECOG, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04334759's enrollment target sits among peer trials
214 1335th of 2000 higher than 666 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04030507 · 214 participants · NA
Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer
- NCT04421248 · 214 participants · Phase 4
Biomarker Validation in Motor System Physiology in Attention Deficit Hyperactivity Disorder
- NCT04667520 · 214 participants · NA
Testing a Lifestyle Physical Activity Intervention for Women With Depression in Alcohol Treatment
- NCT05418868 · 214 participants · Phase 1
A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI